IRVINE, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to participate at two investor conferences in September 2016. The first conference is the Morgan Stanley Global Healthcare Conference 2016 in New York, NY.
|Event:||Morgan Stanley Global Healthcare Conference 2016|
|Date:||Tuesday, September 13, 2016|
|Time:||5:15 pm ET / 2:15 pm PT|
The second conference is the 7th Annual Credit Suisse Small & Mid Cap Conference in New York, NY. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
|Event:||7th Annual Credit Suisse Small & Mid Cap Conference|
|Date:||Wednesday, September 14, 2016|
An audio webcast of the Company’s presentation at the Morgan Stanley Global Healthcare Conference 2016 will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020